The Pedro J. Romero Award recognizes individuals who have made outstanding contributions to the cancer immunotherapy fieldSecond SITC award this year to Professor Melief who will be honoured at the 37th SITC Annual Meeting
Oegstgeest, 8 September 2022 – ISA is delighted to announce that our CSO Professor Dr. Cornelis “Kees” Melief has been awarded the 2022 Pedro J. Romero Service to JITC Award by the Society for Immunotherapy of Cancer (SITC). This Award recognizes individuals who made immeasurable contributions to the Journal for Immunotherapy of Cancer (JITC) – the official journal of the SITC. The award will be presented at the SITC’s 37th
Recognition of commendable, longstanding dedication to the field of cancer immunotherapy
Oegstgeest, 15 July 2022 – ISA is delighted to announce that our Chief Scientific Officer (CSO) and Founder, Professor Dr. Cornelis “Kees” Melief has been nominated and selected by the Board of Directors of the Society for Immunotherapy of Cancer (SITC) as a Fellow of the Academy of Immuno-Oncology (FAIO) . The fellowship recognises Prof. Melief’s inspiring contributions and dedication to cancer immunotherapy, and will be presented at the SITC’s 37th Annual Meeting in Boston, 8-12 November 2022.
SITC is a professional society of scientists, clinicians, government representatives, and industry leaders
Interview with ISA Pharmaceuticals’ CSO, Professor Kees Melief on the need for a therapeutic that specifically drives the T cell immune response against SARS-CoV2.
Winter can be the worst time for respiratory diseases. As the nights draw in and we huddle together against the cold and dark, sneezing and wheezing, we spread our coughs, colds, and worse. Many people can find breathing a struggle in a normal winter, and this year there is the COVID-19 virus stalking the land, seeking lungs to infiltrate, causing the terrible pandemic that we are all caught up in. Whilst the news is, finally, full